FELICIA MEILA

Allopathic & Osteopathic Physicians|Internal Medicine PAWTUCKET, RI NPI 1720049802

General Payments — all program years on this page

$1,460.74

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 78
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $378.06 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $378.0619

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $208.8711
2019 $98.006
2020 $15.581
2021 $248.6114
2022 $189.4910
2023 $322.1317
2024 $378.0619

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096893539 Novo Nordisk Inc $19.60 08/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101746084 E.R. Squibb & Sons, L.L.C. $17.24 08/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104331214 AstraZeneca Pharmaceuticals LP $23.81 06/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105017752 ABBVIE INC. $29.98 08/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105017754 ABBVIE INC. $14.35 10/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105385996 AstraZeneca Pharmaceuticals LP $17.99 09/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105622293 AstraZeneca Pharmaceuticals LP $27.39 05/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117765823 Corcept Therapeutics $23.38 10/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118126419 Boehringer Ingelheim Pharmaceuticals, Inc. $25.73 04/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125216264 Abbott Laboratories $16.72 01/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125837449 Alnylam Pharmaceuticals Inc. $17.50 03/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131783332 PFIZER INC. $20.63 06/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1134972311 Lilly USA, LLC $16.28 02/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147321361 Mylan Specialty L.P. $15.24 02/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148889877 Sumitomo Pharma America, Inc. $18.13 12/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153424131 Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.57 11/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153451255 Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.19 06/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153596207 Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.14 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153653774 Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.19 04/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.